Regeneron Pharmaceuticals Inc. (REGN) Stock
NASDAQREGN has an Alpha Score of 58 out of 100 (moderate), computed on Oct 28, 2026 from 3 of 4 sub-scores. 18 members of Congress disclosed 63 trades in REGN since 2014: 29 purchases and 34 sales, most recently Gilbert Cisneros (sale, May 15, 2026). 8 of the hedge funds AlphaScala tracks reported REGN in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $102.96M. Company insiders reported 0 open-market buys and 32 sales on SEC Form 4 in the 90 days to Oct 30, 2026. Its trailing P/E ratio is 19.3 and its net margin 27.9% (key statistics as of Oct 22, 2026).
What is REGN's Alpha Score?
How it works →Alpha Score of 58 reflects moderate overall profile with strong momentum, moderate value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 28, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Regeneron Pharmaceuticals Inc. (REGN)?
Most recent: Gilbert Cisneros (sale, May 15, 2026); records start Jan 30, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-05-15 | sale | $1k – $15k |
| Alan Armstrong R-OK · Senate | 2026-03-27 | purchase | $1k – $15k |
| Julia Letlow R-LA · House | 2026-02-12 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-11-18 | purchase | $1k – $15k |
| Rob Bresnahan R-PA · House | 2025-05-15 | purchase | $1k – $15k |
| Byron Donalds R-FL · House | 2025-04-10 | sale | $1k – $15k |
| Rob Bresnahan R-PA · House | 2025-04-08 | sale | $1k – $15k |
| Jefferson Shreve R-IN · House | 2025-04-07 | sale | $15k – $50k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded REGN, with filing lags →Which hedge funds own REGN?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 165K | $102.96M | +163% |
| Renaissance Technologies Jim Simons (founder) | 148K | $92.42M | +122% |
| Citadel Ken Griffin | 58K | $35.92M | +21% |
| Bridgewater Associates Ray Dalio | 51K | $32.01M | +126% |
| D.E. Shaw David Shaw | 38K | $23.99M | +69% |
| Marshall Wace | 23K | $14.34M | +6416% |
| Hussman Investment Trust John Hussman | 5K | $3.27M | NEW |
| Blackstone | 3K | $1.57M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Regeneron Pharmaceuticals Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 14, 26 | Murphy Andrew J | Co-Chief Scientific Officer | SELL | 6 | $5K |
| Oct 14, 26 | Murphy Andrew J | Co-Chief Scientific Officer | SELL | 35 | $26K |
| Oct 14, 26 | Murphy Andrew J | Co-Chief Scientific Officer | SELL | 16 | $12K |
| Oct 14, 26 | Murphy Andrew J | Co-Chief Scientific Officer | SELL | 24 | $18K |
| Oct 14, 26 | Murphy Andrew J | Co-Chief Scientific Officer | SELL | 14 | $11K |
| Oct 14, 26 | Murphy Andrew J | Co-Chief Scientific Officer | SELL | 74 | $56K |
| Oct 14, 26 | Murphy Andrew J | Co-Chief Scientific Officer | SELL | 27 | $21K |
| Oct 14, 26 | Murphy Andrew J | Co-Chief Scientific Officer | SELL | 55 | $42K |
| Oct 14, 26 | Murphy Andrew J | Co-Chief Scientific Officer | SELL | 25 | $19K |
| Oct 14, 26 | Murphy Andrew J | Co-Chief Scientific Officer | SELL | 219 | $167K |
SEC Form 4 filings as of Oct 30, 2026
See cluster-buy signals across all tickers →What are REGN's key statistics?
Key statistics as of Oct 22, 2026
How does REGN's valuation compare with the Healthcare sector?
| Metric | REGN | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 19.3 | 27.1 | 97 |
| Net margin | 27.86% | 5.48% | 139 |
| Return on equity | 13.81% | 6.84% | 158 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.
REGN price chart
Powered by TradingViewWhat does Regeneron Pharmaceuticals Inc. do?
Regeneron Pharmaceuticals discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company operates across multiple therapeutic areas, with flagship products including Eylea and Eylea HD for eye diseases such as wet age-related macular degeneration and diabetic macular edema; Dupixent for atopic dermatitis, asthma, and allergic conditions; Libtayo for cutaneous squamous cell carcinoma and other cancers; and Kevzara for rheumatoid arthritis. Regeneron also develops monoclonal and bispecific antibodies through collaborations with partners like Sanofi, and maintains early-stage partnerships in gene editing and RNA interference technologies. The company employs proprietary VelociSuite technologies, including VelocImmune, to accelerate drug development by utilizing genetically humanized mice to produce optimized fully human antibodies. Founded in 1988 and headquartered in Tarrytown, New York, Regeneron serves patients across oncology, immunology, ophthalmology, and cardiovascular disease markets globally.